NovoCure Ltd logo

NovoCure Ltd

FRA:038 (Jersey)  
€ 12.71 (-4.29%) Mar 18
At Loss
P/B:
4.13
Market Cap:
€ 1.36B ($ 1.48B)
Enterprise V:
€ 1.07B ($ 1.16B)
Volume:
-
Avg Vol (2M):
133.00
Also Trade In:

Business Description

Description
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
Name Current Vs Industry Vs History
Cash-To-Debt 1.53
Equity-to-Asset 0.32
Debt-to-Equity 1.65
Debt-to-EBITDA -3.36
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 1/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0.73
Distress
Grey
Safe
Beneish M-Score -3.19
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 18.74
9-Day RSI 32.03
14-Day RSI 39.49
6-1 Month Momentum % -18.69
12-1 Month Momentum % -73.06

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 5.78
Quick Ratio 5.56
Cash Ratio 5.08
Days Inventory 96.22
Days Sales Outstanding 51.37
Days Payable 240.86

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -1.5
Shareholder Yield % -0.88

Financials (Next Earnings Date:2024-05-03 Est.)

FRA:038's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

NovoCure Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 472.443
EPS (TTM) (€) -1.809
Beta 0.56
Volatility % 74.6
14-Day RSI 39.49
14-Day ATR (€) 0.507084
20-Day SMA (€) 14.36625
12-1 Month Momentum % -73.06
52-Week Range (€) 10.325 - 78.3
Shares Outstanding (Mil) 107.09

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 1
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

NovoCure Ltd Filings

Filing Date Document Date Form
No Filing Data

NovoCure Ltd Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

NovoCure Ltd Frequently Asked Questions

What is NovoCure Ltd(FRA:038)'s stock price today?
The current price of FRA:038 is €12.71. The 52 week high of FRA:038 is €78.30 and 52 week low is €10.33.
When is next earnings date of NovoCure Ltd(FRA:038)?
The next earnings date of NovoCure Ltd(FRA:038) is 2024-05-03 Est..
Does NovoCure Ltd(FRA:038) pay dividends? If so, how much?
NovoCure Ltd(FRA:038) does not pay dividend.

Press Release

Subject Date
No Press Release